Clinical trials: Patients With Major Depressive Disorder
Major Depressive Disorder
Major Depressive Disorder - Understanding The Link Between The Brain And The Heart
There is strong evidence that patients with major depressive disorder (MDD) have an increased risk of developing coronary heart disease (CHD).
- Trial name
- MDD (NCT01568307)
- Testing
- Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.
- Where
- 4 sites in Australia
- Volunteers
- 80 people
- Sponsor
- Baker Heart and Diabetes Institute
Major Depressive Disorder
A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder
MIN-117C03 is a 6-week, 3-arm, randomized, double-blind, placebo controlled study to investigate the safety and efficacy of MIN-117 in male and female patients with Major Depressive Disorder, aged 18 to 65 years.
- Trial name
- NCT03446846
- Testing
- MIN-117 5.0 mg, MIN-117 2.5 mg
- Where
- 47 sites in United States, Bulgaria and 5 more
- Volunteers
- 360 people
- Sponsor
- Minerva Neurosciences
Major Depressive Disorder
Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)
A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression.
- Trial name
- NCT00048594
- Testing
- aprepitant
- Volunteers
- 800 people
- Sponsor
- Merck Sharp & Dohme LLC
Depression Chronic, Depression and Quality of Life
Remote Medical Monitoring of Patients With Depression
The goal of this clinical trial is to learn if ThIA Suivi, a digital tool for remote monitoring of patients, can improve the care of adults with depression who are followed by a psychiatrist.
- Conditions
- Depression Chronic, Depression and Quality of Life, Depression, Major Depressive Episode
- Trial name
- TELEMED-DEP (NCT07878754)
- Testing
- Use of ThIA Medical Device
- Where
- 3 sites in France
- Volunteers
- 608 people
- Sponsor
- ThIA Santé Mentale
Major Depressive Disorder
Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD)
The objective of this study is to allow patients who have participated in the precursor study of BCI-024 in combination with BCI-049 versus placebo or BCI-024 alone (Protocol #CBM-IT-01) to receive 6 weeks of open-label treatment…
- Trial name
- NCT00731653
- Testing
- Combination Product: BCI-024 + BCI-049
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- Massachusetts General Hospital
Bipolar Disorder, Cognitive Impairment
Effects of Erythropoietin on Cognition and Neural Activity in Mood Disorders
The present trial consists of 2 sub-studies that investigate important novel aspects of treatment with erythropoietin (EPO) on cognitive dysfunction in bipolar disorder (BD) and recurrent unipolar depressive disorder (UD)…
- Conditions
- Bipolar Disorder, Cognitive Impairment, Unipolar Depression
- Trial name
- PreTEC-EPO (NCT03315897)
- Testing
- Erythropoietin, Saline
- Where
- Denmark
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Lars Vedel Kessing
Schizophrenia, Schizoaffective Disorder
Get Moving and Get Well - Pilot Study
Individuals with serious mental illness have greater morbidity from physical illness and mortality than the general population, but tend not to initiate or sustain engagement in health promotion interventions.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depression
- Trial name
- GMGWP (NCT01884025)
- Testing
- Get Moving and Get Well, Health and Humor Class
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Major Depression
Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression
The steroid hormone cortisol is released in response to stress and acts in the central nervous system upon glucocorticoid (GR) and mineralocorticoid receptors (MR).
- Trial name
- MISO (NCT03062150)
- Testing
- Fludrocortisone, D-Cycloserine
- Where
- Germany
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
Major Depressive Disorder
A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder
The main aim of the study is to check how well vortioxetine 10 mg/day or 20 mg/day works and to check for side effects compared to a placebo on depression symptoms in Japanese teenagers aged 12 to 17 years with a diagnosis of…
- Trial name
- NCT07204314
- Testing
- Vortioxetine tablets
- Where
- 30 sites in Japan
- Volunteers
- 180 people
- Sponsor
- Takeda
Atopic Dermatitis
A Study to Evaluate the Quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermatitis Treated With Dupilumab in Czech Republic
Assessment of the relationship between treatment response (EASI75) and change in quality of life (EQ-5D) by week 24. Description of the: Change in disease activity after 16 and 24 weeks Change in subject and family quality of…
- Trial name
- NCT05527964
- Where
- Czechia
- Volunteers
- 146 people
- Sponsor
- Sanofi
Depressive Disorder
Memory Changes in Patients With Major Depression Disorder Treated With ECT
The basic memory changes (impairment) present in patients with major depression and the influence of the treatment with ECT.
- Trial name
- NCT03915821
- Testing
- ECT
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Assiut University
Major Depression, Tobacco Addiction
Transcranial Magnetic Stimulation in Patients with Dual Disorders
According to the WHO, 280 million people are diagnosed with depression, the prevalence of which is almost twice as high in women as in men, with the incidence among young people increasing in recent years.
- Trial name
- NCT06765824
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- Spain
- Volunteers
- 36 people
- Sponsor
- Cardenal Herrera University
Major Depressive Disorder
Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults
The purpose of the study is to evaluate the efficacy, tolerability and the safety of two fixed doses of vortioxetine in the treatment of major depressive disorder.
- Trial name
- NCT01140906
- Testing
- Vortioxetine (Lu AA21004), Duloxetine
- Volunteers
- 607 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Efficacy and Safety of DOV 21,947 in the Treatment of Major Depressive Disorder
The primary objectives of this placebo-controlled trial are to evaluate effectiveness and safety of DOV 21,947 at two oral dose levels.
- Trial name
- NCT00659347
- Testing
- DOV 21, 947
- Where
- 26 sites in United States, Romania and 1 more
- Volunteers
- 200 people
- Sponsor
- DOV Pharmaceutical, Inc.
Major Depressive Disorder
Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder
The purpose of this study is to assess the effect of escitalopram on sleep architecture utilizing a prospective design. Hypothesis: Escitalopram will improve REM latency in patients with MDD that have responded clinically to…
- Trial name
- NCT00442481
- Testing
- Escitalopram, A baseline overnight polysomnography (oPSG)
- Where
- Israel
- Volunteers
- 25 people
- Sponsor
- Sheba Medical Center
Major Depressive Disorder
The Effect of Patient and Investigator Expectation on the Efficacy of Escitalopram in the Treatment Depression
To evaluate the effect of visit number, patient expectation, and rater expectation of the efficacy of escitalopram treatment in fixed doses of 10 and 20mg, based on baseline severity in patients with MDD.
- Trial name
- NCT02480400
- Testing
- Escitalopram
- Where
- Israel
- Volunteers
- 52 people
- Sponsor
- Abarbanel Mental Health Center
Major Depressive Disorder
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders…
- Trial name
- NCT05061706
- Testing
- Lumateperone
- Where
- 50 sites in United States, Argentina and 5 more
- Volunteers
- 480 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Major Depressive Disorder (MDD)
A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
The purpose of this study is to assess if LY2216684 (flexible dose of 12 to 18 milligrams [mg] or fixed dose of 6 mg once daily) is superior to placebo once daily in the adjunctive treatment of participants with Major Depressive…
- Trial name
- NCT01187407
- Testing
- LY2216684, SSRI
- Where
- 54 sites in United States, Croatia and 5 more
- Volunteers
- 1,480 people
- Sponsor
- Eli Lilly and Company
Major Depression, Repetitive Transcranial Magnetic Stimulation
Using EEG to Predict Depression Treatment Response to rTMS in Patients With Major Depression
Repetitive Transcranial Magnetic Stimulation (rTMS) is a promising, novel, non-invasive therapy for depression. The study is looking at changes in specific electroencephalogram parameters in depressed patients treated with rTMS…
- Trial name
- NCT04575285
- Testing
- Electroencephalogram (EEG)
- Where
- United States
- Sponsor
- Baptist Health South Florida
Depressive Disorder, Depressive Disorder, Major
The Efficacy of Acupressure Therapy on Patient With Depression
A new nursing intervention with non-invasive acupressure protocol for activation of parasympathetic nervous system to reduce stress related depression symptoms.
- Conditions
- Depressive Disorder, Depressive Disorder, Major, Depressive Symptoms
- Trial name
- Akupress (NCT05423405)
- Testing
- Acupressure
- Volunteers
- 150 people
- Sponsor
- University Psychiatric Clinics Basel